Forecasting thrombotic complications in patients with community acquired pneumonia according to multidimensional analysis of severity, systematic inflammation, endothelial function and hemostasis
BACKGROUND. Despite the significant progress in the diagnostic and treatment of community-acquired pneumonia (CAP), the issues of timely defining thrombotic complications of CAP and their timely treatment have not yet been fully resolved.
OBJECTIVE. To determine the prognostic signs of the risk of thrombotic complications in patients with CAP.
MATERIALS AND METHODS. Thus, 45 patients with CAP of the 3rd and 4th clinical groups were examined. The result of the cluster analysis was the distribution of patients into certain clusters (classes). There were 3 clusters of patients depending on the predisposition to thrombosis.
RESULTS AND DISCUSSION. Patients belonging to cluster 2 and cluster 3 had a high risk of thrombosis. A feature of these patients was a severe course of CAP (by SMRT-CO scale), accompanied by significant leukocytosis or leukopenia in combination with severe systemic inflammation (C-reactive protein) and low protein C.
CONCLUSIONS. This category of patients should consider the possibility of prescribing anticoagulant therapy. While in patients with mild CAP, less pronounced systemic inflammation and high levels of protein C, the risk of thrombosis will be low. Therefore, this category of patients will not require the appointment of anticoagulants.
Adapted evidence-based clinical guidelines “Community-acquired pneumonia in adults: etiology, pathogenesis, classification, diagnosis, antimicrobial therapy and prevention”. Kyiv: National Academy of Medical Sciences of Ukraine, 2019. 94 p.
Pertseva T.O., Kireeva T.V., Bielosludtseva K.O. Retrospective analysis of fatal cases of severe community-acquired pneumonia: “masks of severe pneumonia”. Ukr. Pulmonol. Journal. 2013; 2: 26-30.
Approval of clinical protocols “Pulmonology” for treatment and management. Decree of the Ministry of Health of Ukraine № 128 of March 19, 2007. Kyiv, 2007. 146 p.
Cecere L.M., Rubenfeld G.D., Park D.R., Root R.K., Goss C.H. Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration. 2010; 79: 128-36.
Chen L.F., Chen H.P., Huang Y.S., Huang K.Y., Chou P., Lee C.C. Pneumococcal pneumonia and the risk of stroke: a population based follow-up study. PLoS One. 2012; 7 (12): e51452.
Clayton T.C., Gaskin M., Meade T.W. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. International J. of Epidemiology. 2011; 40: 819-27.
Daniel P., Woodhead M., Welham S., Mckeever T.M. Mortality reduction in adult community-acquired pneumonia in the UK (2009-2014): results from the British Thoracic Society audit programme. Thorax. 2016; 71 (11): 1061-3.
Haixia Z., Yuehong H., Xiaoqian L., Lan W., Maoyun W., Jun X., et al. Assessment of the risk of venous thromboembolism in medical ICA patients using the Padua prediction score and Caprini risk assessment model. J. of Atherosclerosis and Thrombosis. 2018; 25 (11): 1091-104.
Khalafian A.A. Statisticа 6. Statistical analysis of data. OOO “Bynom-Press”, 2007. 512 p. In Russian.
Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K. et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med. 2019; 200 (7): e45-e67.
This work is licensed under a Creative Commons Attribution 4.0 International License.